Clinical trial
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation
NCT05194124 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 21, 2021
- Completion date
- October 19, 2023
- Enrollment
- 19 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
bardet-biedl syndrome, pomc deficiency